Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Paroxechem -25 CR Paroxetine Tablets 25 mg
Paroxechem -25 CR Paroxetine Tablets 25 mg offers a sustained-release formulation that helps manage symptoms of depression and anxiety more consistently. As a controlled-release (CR) tablet, it provides a steady release of paroxetine, which enhances patient compliance and reduces the frequency of dosing.
Uses of Paroxechem -25 CR Paroxetine Tablets 25 mg
Major Depressive Disorder: Helps alleviate symptoms such as sadness, loss of interest, and fatigue.
Generalized Anxiety Disorder: Reduces excessive worry and anxiety symptoms.
Obsessive-Compulsive Disorder (OCD): Decreases obsessive thoughts and compulsive behaviors.
Panic Disorder: Prevents panic attacks and reduces associated anxiety.
Social Anxiety Disorder: Improves symptoms related to social phobia.
Benefits of Paroxechem -25 CR Paroxetine Tablets 25 mg
Consistent Therapeutic Effect: The controlled-release formulation ensures a steady release of medication, providing sustained relief from symptoms.
Reduced Dosing Frequency: Typically requires once-daily dosing, improving adherence to treatment.
Effective for Multiple Disorders: Addresses a range of psychiatric conditions, including depression and various anxiety disorders.
Improved Tolerability: Controlled release may help minimize side effects commonly associated with SSRIs, such as gastrointestinal discomfort and insomnia.
Proven Efficacy: Widely studied and used in clinical practice for its effectiveness in treating mood and anxiety disorders.
Mechanism of Action of Paroxechem -25 CR Paroxetine Tablets 25 mg
The active ingredient in Paroxechem -25 CR Paroxetine Tablets 25 mg is paroxetine, an SSRI. Paroxetine works by inhibiting the reuptake of serotonin, a neurotransmitter, into the presynaptic neuron in the brain. Serotonin plays a crucial role in mood regulation, and increasing its availability in the synaptic cleft enhances neurotransmission.